Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 16/09/2026

3,030 USD (-0,33%)

(-0,33%) 16/09/2026

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d -0,33%
1 week1w -3,19%
1 maand1m -3,81%
3 maanden3m -0,66%
6 maanden6m -19,84%
1 jaar1j 0,33%
5 jaar5j -61,79%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

14 september 2026 · Evaxion applies its AI-Immunology™ platform in autoimmune diseases · Persbericht

20 augustus 2026 · Evaxion announces business update and second quarter 2026 financial results · Persbericht

17 augustus 2026 · Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program · Persbericht

14 augustus 2026 · Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 · Persbericht

17 juli 2026 · Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 · Persbericht

12 juli 2026 · Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 · Persbericht

1 juli 2026 · Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop · Persbericht

12 juni 2026 · Evaxion receives Prix Galien UK Award for Best digital health solution · Persbericht

11 juni 2026 · Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia · Persbericht

12 mei 2026 · Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe